To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
VC-backed Lyell Immunopharma raises $425m for IPO
Lyell Immunopharma, a T-cell reprogramming company, has raised about $425 million for its IPO after pricing its 25 million shares at $17 per share.
